Wanner Pharmaceuticals Receives Drug Registration Certificate for Betaprost Sodium Tablets on May 22

GateNews
On May 22, Wanner Pharmaceuticals announced it received a Drug Registration Certificate from China's National Medical Products Administration (NMPA) for Betaprost Sodium Tablets. The drug is indicated to improve symptoms of chronic arterial occlusive disease, including ulcers, intermittent claudication, pain, and cold sensation. The product is deemed to have passed consistency evaluation and expands the company's pharmaceutical portfolio.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments